Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Noxopharm Ltd V.NOX


Primary Symbol: NOXOF

Noxopharm Limited is a biotech company. It is engaged in discovering and developing novel treatments for cancer and inflammation, including a pioneering technology to enhance messenger ribonucleic acid (mRNA) vaccines. It utilizes specialist in-house capabilities and partnerships with researchers to build a pipeline of new proprietary drugs based on two technology platforms: Chroma (oncology) and Sofra (inflammation, autoimmunity, and mRNA vaccine enhancement). Chroma is a technology platform focused on the development of multiple drug candidates, primarily for cancer treatment. The Sofra technology platform has a pipeline of proprietary drugs based on oligonucleotides, the building blocks of deoxyribonucleic acid (DNA), with a focus on mRNA vaccines and the treatment of autoimmune and inflammatory diseases. SOF-VAC has applications in the treatment of excessive inflammatory responses associated with specialized inflammatory receptors in the body known as Toll-like receptor 7.


OTCPK:NOXOF - Post by User

Post by MrMonkon Jan 20, 2015 9:45pm
200 Views
Post# 23342123

Further update from Investor Relations

Further update from Investor RelationsReceived this today from IR:

The new directors/President are well known and that is helping bring in new buyers. The drill results are very good and open up some new resources in the pit shell in areas that were previously classified as waste rock, so that improves the economics of the Marban deposit. Our plan is to complete 40,000 meters on the Marban and update the 43-101 by year-end with  the goal to up-grade the resources to reserve status. This will make Marban ready for a production decision early next year. If that happens we will see a revaluation of the stock by funds. We have been meeting lots of people who made money on Osisko that like our new directors and understand the plan to either produce or sell the ore to the Canadian Malartic mill – thus saving $500,000,000 in construction and making NioGold cash flow positive very quickly. We are dealing with a whole new group of investors now. Gold stronger is helping too.
 
Things are looking up, and we may never see these prices again!

- MM
<< Previous
Bullboard Posts
Next >>